1 Study Coverage
1.1 Primary Biliary Cirrhosis Drug Product Introduction
1.2 Market Segments
1.3 Key Primary Biliary Cirrhosis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type
1.4.2 Budesonide
1.4.3 FFP-104
1.4.4 GSK-2330672
1.4.5 MBX-8025
1.4.6 NGM-282
1.4.7 Others
1.5 Market by Application
1.5.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Primary Biliary Cirrhosis Drug Market Size, Estimates and Forecasts
2.1.1 Global Primary Biliary Cirrhosis Drug Revenue 2015-2026
2.1.2 Global Primary Biliary Cirrhosis Drug Sales 2015-2026
2.2 Global Primary Biliary Cirrhosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Primary Biliary Cirrhosis Drug Competitor Landscape by Players
3.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers
3.1.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Primary Biliary Cirrhosis Drug Revenue by Manufacturers
3.2.1 Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Revenue in 2019
3.2.5 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Primary Biliary Cirrhosis Drug Price by Manufacturers
3.4 Primary Biliary Cirrhosis Drug Manufacturing Base Distribution, Product Types
3.4.1 Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Primary Biliary Cirrhosis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
4.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020)
4.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020)
4.1.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Primary Biliary Cirrhosis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Primary Biliary Cirrhosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
5.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020)
5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2015-2020)
5.1.3 Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
5.2 Primary Biliary Cirrhosis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Primary Biliary Cirrhosis Drug by Country
6.1.1 North America Primary Biliary Cirrhosis Drug Sales by Country
6.1.2 North America Primary Biliary Cirrhosis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
6.3 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Primary Biliary Cirrhosis Drug by Country
7.1.1 Europe Primary Biliary Cirrhosis Drug Sales by Country
7.1.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
7.3 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Primary Biliary Cirrhosis Drug by Region
8.1.1 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region
8.1.2 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
8.3 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Primary Biliary Cirrhosis Drug by Country
9.1.1 Latin America Primary Biliary Cirrhosis Drug Sales by Country
9.1.2 Latin America Primary Biliary Cirrhosis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
9.3 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Primary Biliary Cirrhosis Drug by Country
10.1.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country
10.1.2 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Application

11 Company Profiles
11.1 AlbireoPharma
11.1.1 AlbireoPharma Corporation Information
11.1.2 AlbireoPharma Description and Business Overview
11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
11.1.5 AlbireoPharma Related Developments
11.2 CymaBay Therapeutics, Inc.
11.2.1 CymaBay Therapeutics, Inc. Corporation Information
11.2.2 CymaBay Therapeutics, Inc. Description and Business Overview
11.2.3 CymaBay Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.2.5 CymaBay Therapeutics, Inc. Related Developments
11.3 Dr. Falk Pharma GmbH
11.3.1 Dr. Falk Pharma GmbH Corporation Information
11.3.2 Dr. Falk Pharma GmbH Description and Business Overview
11.3.3 Dr. Falk Pharma GmbH Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products Offered
11.3.5 Dr. Falk Pharma GmbH Related Developments
11.4 Enanta Pharmaceuticals, Inc.
11.4.1 Enanta Pharmaceuticals, Inc. Corporation Information
11.4.2 Enanta Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Enanta Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.4.5 Enanta Pharmaceuticals, Inc. Related Developments
11.5 GlaxoSmithKline Plc
11.5.1 GlaxoSmithKline Plc Corporation Information
11.5.2 GlaxoSmithKline Plc Description and Business Overview
11.5.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products Offered
11.5.5 GlaxoSmithKline Plc Related Developments
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Corporation Information
11.6.2 Intercept Pharmaceuticals, Inc. Description and Business Overview
11.6.3 Intercept Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.6.5 Intercept Pharmaceuticals, Inc. Related Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Description and Business Overview
11.7.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products Offered
11.7.5 Johnson & Johnson Related Developments
11.8 MediGene AG
11.8.1 MediGene AG Corporation Information
11.8.2 MediGene AG Description and Business Overview
11.8.3 MediGene AG Sales, Revenue and Gross Margin (2015-2020)
11.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products Offered
11.8.5 MediGene AG Related Developments
11.9 NGM Biopharmaceuticals, Inc.
11.9.1 NGM Biopharmaceuticals, Inc. Corporation Information
11.9.2 NGM Biopharmaceuticals, Inc. Description and Business Overview
11.9.3 NGM Biopharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.9.5 NGM Biopharmaceuticals, Inc. Related Developments
11.10 Virobay Inc.
11.10.1 Virobay Inc. Corporation Information
11.10.2 Virobay Inc. Description and Business Overview
11.10.3 Virobay Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products Offered
11.10.5 Virobay Inc. Related Developments
11.1 AlbireoPharma
11.1.1 AlbireoPharma Corporation Information
11.1.2 AlbireoPharma Description and Business Overview
11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
11.1.5 AlbireoPharma Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Primary Biliary Cirrhosis Drug Market Estimates and Projections by Region
12.1.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.2.2 North America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Primary Biliary Cirrhosis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Primary Biliary Cirrhosis Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Primary Biliary Cirrhosis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer